Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act
by Robin Feldman
In this Policy Forum piece, Robin Feldman discusses how current legislation contributes to informational deficits around drug patents for biologic drugs in the United States.
Source: PLoS Medicine - Category: Internal Medicine Authors: Robin Feldman Source Type: research
More News: Internal Medicine | USA Health